Abstract Psychedelic-assisted therapies are emerging as novel treatments of interest for a range of mental health issues, including eating disorders such as anorexia nervosa. Psychedelics, such as LSD and psilocybin, may exert biological and psychological effects pertinent to the pathophysiology of eating disorders. Initial clinical trials are underway to confirm the safety and therapeutic...
Die psychedelika assistierte Psychotherapie erfährt aktuell eine wissenschaftlich fundierte Renaissance. Studien zeigen eine therapeutische Wirksamkeit von Substanzen wie Psilocybin, LSD und MDMA bei verschiedenen psychischen Störungsbildern, insbesondere bei therapieresistenter Depression, PTBS, Angstund Suchterkrankungen. In der Schweiz nimmt diese Entwicklung eine besondere Stellung ein: Als...
Social WorkOctober 1, 2025Heidi L Allen, Brooke L Stott
With MDMA, LSD, and psilocybin receiving “Breakthrough Therapy” designation by the U.S. Food and Drug Administration (FDA) and moving into Phase 3 clinical trials, we are closer than ever to legal administration of these compounds for mental health treatment. Research from Lykos, Usona Institute, Mindmed, Compass Pathways, and Johns Hopkins, among others, has shown promising efficacy of the...
Treatment-resistant depression (TRD) remains a major therapeutic challenge in psychiatry, affecting a substantial proportion of individuals diagnosed with major depressive disorder and contributing significantly to the overall burden of mental illness. Despite decades of research and the availability of numerous antidepressant agents, many patients fail to achieve full remission, which...
Psychedelics, such as psilocybin, lysergic acid diethylamide (LSD), ketamine, and N,N-dimethyltryptamine (DMT), have captured the attention of scientists, artists, and seekers alike for their profound ability to alter consciousness and inspire creativity. The concept of "creation" encompasses multiple interpretations-ranging from generating novel ideas to fostering personal transformation. This...
This study explores how individuals from ethnoracially marginalized backgrounds engage with psychedelic substances for psychological healing, cultural reconnection, and resistance to structural neglect in mainstream health care systems. Based on 23 in-depth interviews and participant-observation within a psychedelic preparation and integration training program, the research documents how...
Both meditation and psychedelics are widely studied for their therapeutic potential in mental health. Recent research suggests potential synergies between mindfulness practice and psychedelics, though empirical studies have primarily focused on psilocybin. This study investigates the distinct and combined effects of mindfulness practice and an ayahuasca-inspired formulation containing...
Major depression affects about 280 million people worldwide and costs around 326 billion dollars per year in the United States, though the standard medications take 2-3 months to take effect, so faster and longer-lasting treatments are needed.Serotonergic psychedelics such as psilocybin, DMT or ayahuasca, LSD, and mescaline can reduce depression and anxiety symptoms after only one or two doses,...
Psychedelic-assisted therapy (PAT) frequently utilises a “cotherapy” model, in which two therapists jointly support participants or patients through preparation, dosing, and integration sessions. While common in clinical trials, the experience of cotherapy from the participant perspective remains underexplored. This qualitative study examined experiences of cotherapy within a trial of...
Introduction: Treatment-Resistant Depression (TRD) affects approximately 30–50% of patients with Major Depressive Disorder (MDD) who fail to respond to at least two adequate antidepressant trials. This condition presents substantial clinical and functional challenges, and no universally accepted treatment algorithm currently exists. Emerging therapeutic strategies, particularly glutamatergic...